A review finds that GLP-1 receptor agonists offer wide-ranging benefits beyond blood sugar and weight control, including organ protection, reduced ischemia injury, substance use disorder treatment, and effects on tumor growth and bone metabolism.
7+ benefit categories beyond diabetes/obesityGLP-1 receptor agonists show promise in ischemia protection, organ function, addiction, cancer, bone health, gut microbiota, and transplant survival.
What the researchers found
The review identified multiple beneficial effects of GLP-1 receptor agonists beyond their established roles in diabetes and obesity management. These include reducing ischemia-reperfusion injury (damage caused when blood flow returns after being cut off), improving function across various organs, alleviating substance use disorders, influencing tumor development, regulating bone metabolism, modifying gut microbiota composition, and prolonging the survival of transplanted organs.
These diverse effects point to GLP-1 receptors being present and functionally important in many tissues throughout the body, not just the pancreas and brain regions controlling appetite.
Why it matters
GLP-1 receptor agonists like semaglutide and liraglutide are among the most widely prescribed drugs in the world. Understanding their effects beyond blood sugar and weight could reshape how they are used clinically — potentially benefiting patients with heart disease, addiction, organ transplants, and other conditions. This broadening scope may also reveal new insights about how GLP-1 signaling works throughout the body.
How the study worked
This is a narrative review article that summarized published research on the non-diabetic and non-obesity-related effects of GLP-1 receptor agonists. The authors compiled findings from existing studies across multiple therapeutic areas.
What this study cannot tell us
As a narrative review, this paper summarizes existing research but does not conduct new experiments or perform a systematic meta-analysis. The strength of evidence varies widely across the different benefit categories discussed — some are supported by large clinical trials while others rely on preclinical animal data. The review does not assess the quality or risk of bias across the cited studies.
How to read the evidence
This is a narrative review summarizing findings from multiple studies of varying quality. Reviews are useful for synthesizing knowledge but rank below systematic reviews and meta-analyses because they do not use standardized methods for study selection and quality assessment.
When this study was published
Published in 2024, this review captures the most recent wave of research into GLP-1 receptor agonist benefits, making it highly current and relevant to the rapidly evolving understanding of these drugs.
The bigger picture
The expanding list of GLP-1 receptor agonist benefits reflects a major shift in how these peptide drugs are viewed — from niche diabetes treatments to potential multi-system therapies. Clinical trials are already underway testing these drugs for heart failure, liver disease, Alzheimer's, and addiction, making this review a timely summary of the scientific rationale behind those efforts.
Questions still open
- Which of these emerging benefits will be confirmed by large-scale randomized clinical trials in the coming years?
- Are the non-metabolic effects of GLP-1 receptor agonists dose-dependent, and do they require the same dosing used for diabetes and obesity?
- Could combining GLP-1 receptor agonists with other therapies enhance their protective effects in areas like organ transplantation or substance use disorders?
Common questions
What are GLP-1 receptor agonists and why are they getting so much attention?
Can GLP-1 receptor agonists really help with addiction?
Read the original research
The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties.
Medicina (Kaunas, Lithuania), 61(1)
Citation
Lu, Chenqi; Xu, Cong; Yang, Jun. (2024). The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties.. Medicina (Kaunas, Lithuania), 61(1). https://doi.org/10.3390/medicina61010017